KAT2A and cancer: Overexpression and/or mutation of the bromodomain-containing KAT2A (GCN5) HAT appears to correlate with aggressive cancer progression and poor prognosis for several different cancers including non-small cell lung cancer, hepatocellular carcinoma, breast, colorectal, and prostate cancers [66,67], and is reviewed in [68].